Celldex Therapeutics (CLDX) Profit After Tax (2010 - 2026)

Celldex Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$79.8 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 48.32% year-over-year to -$79.8 million; the TTM figure through Mar 2026 stood at -$285.2 million (down 59.47% YoY), while the FY2025 annual figure was -$258.8 million, down 63.92% from the prior year.
• Profit After Tax for Q1 2026 stood at -$79.8 million, up from -$81.8 million in the prior quarter.
• The five-year high for Profit After Tax was -$24.8 million in Q1 2022, with the low at -$81.8 million in Q4 2025.
• The 5-year median for Profit After Tax is -$38.2 million (2023), against an average of -$44.1 million.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax slumped 173.29% in 2022, then increased 16.37% in 2023.
• Celldex Therapeutics' Profit After Tax stood at -$25.1 million in 2022, then slumped by 67.76% to -$42.1 million in 2023, then decreased by 11.76% to -$47.1 million in 2024, then sank by 73.66% to -$81.8 million in 2025, then rose by 2.42% to -$79.8 million in 2026.
• Business Quant data shows CLDX's Profit After Tax at -$79.8 million in Q1 2026, -$81.8 million in Q4 2025, and -$67.0 million in Q3 2025.